Roivant Sciences Ltd. (NASDAQ:ROIV) Major Shareholder Sells $2,246,952.00 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) major shareholder Vivek Ramaswamy sold 200,800 shares of the business's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $11.19, for a total value of $2,246,952.00. Following the completion of the transaction, the insider now directly owns 38,426,381 shares of the company's stock, valued at approximately $429,991,203.39. This trade represents a 0.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.

Vivek Ramaswamy also recently made the following trade(s):

• On Wednesday, June 4th, Vivek Ramaswamy sold 547,430 shares of Roivant Sciences stock. The shares were sold at an average price of $11.34, for a total value of $6,207,856.20.
• On Tuesday, May 6th, Vivek Ramaswamy sold 273,959 shares of Roivant Sciences stock. The shares were sold at an average price of $11.47, for a total value of $3,142,309.73.

Roivant Sciences Stock Performance

Roivant Sciences stock traded up $0.03 during trading on Friday, reaching $11.23. The company had a trading volume of 4,927,975 shares, compared to its average volume of 5,569,942. The firm's 50-day simple moving average is $10.64 and its 200 day simple moving average is $11.02. The firm has a market capitalization of $8.01 billion, a PE ratio of -74.86 and a beta of 1.16. Roivant Sciences Ltd. has a 1-year low of $8.73 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The company had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. During the same period in the prior year, the firm earned ($0.23) EPS. Analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research report on Wednesday, May 28th.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its position in shares of Roivant Sciences by 0.3% in the fourth quarter. FMR LLC now owns 49,301,583 shares of the company's stock valued at $583,238,000 after buying an additional 156,527 shares during the last quarter. Vanguard Group Inc. grew its stake in Roivant Sciences by 5.8% during the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after acquiring an additional 2,404,232 shares in the last quarter. Patient Square Capital LP raised its holdings in Roivant Sciences by 2.1% in the 4th quarter. Patient Square Capital LP now owns 12,480,000 shares of the company's stock valued at $147,638,000 after acquiring an additional 251,535 shares during the last quarter. Two Seas Capital LP lifted its stake in Roivant Sciences by 4.6% in the 4th quarter. Two Seas Capital LP now owns 10,167,807 shares of the company's stock worth $120,285,000 after purchasing an additional 442,914 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of Roivant Sciences by 3.8% during the 1st quarter. Invesco Ltd. now owns 9,880,526 shares of the company's stock worth $99,695,000 after purchasing an additional 365,468 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.